If you have tried two or more antidepressants and still feel stuck, you are not out of choices. The most effective treatment resistant depression options today include repetitive transcranial magnetic stimulation (TMS), esketamine nasal spray (Spravato), medication augmentation, and, in some cases, electroconvulsive therapy (ECT). This guide explains how psychiatrists define TRD, why first-line medications fall short for some people, and how the newer treatments are combined. If you want to talk through your own history, our team offers comprehensive depression care across California.
What Is Treatment-Resistant Depression?
The standard treatment resistant depression definition is major depressive disorder that has not improved enough after at least two antidepressant trials, each given at an adequate dose for an adequate length of time during the current episode. "Adequate" usually means a therapeutic dose taken consistently for about 6 to 8 weeks. It is the same two-trial threshold the U.S. Food and Drug Administration uses in the labeling for esketamine.
The problem is common. In the NIMH-funded STAR*D trial, the largest real-world study of depression treatment, 4,041 outpatients moved through up to four treatment steps. Only about a third reached remission on their first antidepressant (citalopram). A 2023 reanalysis published in BMJ Open argued that the study's often-quoted 67% cumulative remission rate was closer to 35% when the protocol's own rating scale was applied. Either way, a large share of people need something beyond the first or second pill.
How psychiatrists stage TRD
Not all treatment resistance looks the same. Clinicians often use a staging model to describe how far along someone is:
- Thase-Rush staging (Stages I to V): moves from failure of one antidepressant (Stage I) up to failure of several classes, augmentation, and ECT (Stage V).
- Maudsley Staging Method: scores the length of the episode, symptom severity, and the number and type of failed treatments, including augmentation and ECT.
Staging matters because it guides the choice made during psychiatric medication management. Someone at an early stage may do well with a switch or an add-on medication. Someone who has failed multiple antidepressants plus augmentation is usually a better fit for device-based or rapid-acting care.
Before calling depression "treatment-resistant," a careful psychiatrist also checks for pseudo-resistance: doses that were too low, trials that were too short, missed doses, untreated thyroid disease, sleep apnea, alcohol or cannabis use, or an undiagnosed bipolar disorder. Bipolar depression often responds poorly to antidepressants alone, which is why we screen for it through our specialized bipolar disorder treatment program.
Why Do SSRIs Fail for Some People?
SSRIs act mainly on serotonin, and for many people with chronic depression, the bigger problem appears to involve glutamate signaling and weakened connections between brain cells.
Traditional antidepressants (SSRIs, SNRIs, bupropion, mirtazapine, and tricyclics) work on monoamines: serotonin, norepinephrine, and dopamine. They raise those levels within hours, yet mood usually takes weeks to lift. That gap is a clue that the real benefit comes from slower downstream changes, such as more brain-derived neurotrophic factor (BDNF) and new synapse growth, rather than from the chemical boost itself.
Research on long-standing depression shows reduced synaptic density and lower volume in areas such as the hippocampus and prefrontal cortex. Glutamate is the brain's main excitatory neurotransmitter, and it drives much of this neuroplasticity. When monoamine medications cannot restore those circuits, treatment resistant depression options that act on glutamate or on circuit activity, like esketamine and TMS, give the brain a different route. The NIMH overview of brain stimulation therapies notes that these approaches are usually used after other treatments have been tried, which matches how TRD care is sequenced.
How Does TMS Help TRD?
TMS uses a magnetic coil placed against the scalp to deliver repeated pulses to the left dorsolateral prefrontal cortex, a region that tends to be underactive in depression. The pulses induce small electrical currents that strengthen activity in mood-regulating networks over a series of sessions. No anesthesia is needed; you stay awake, and you can drive yourself home.
Key facts about TMS therapy at APA:
- FDA status: cleared in 2008 for adults with major depression who did not improve on an antidepressant. A faster protocol, intermittent theta burst stimulation, was cleared in 2018.
- Schedule: a standard course runs 5 days a week for about 6 weeks, followed by a taper. Standard sessions last roughly 19 to 37 minutes, and theta burst sessions take about 3 minutes.
- Side effects: mostly scalp discomfort and headache during the first week. Seizures are rare.
- Outcomes: a 2012 multisite study of 307 patients treated in regular clinical practice found that 58% responded and 37% reached remission.
TMS suits people who cannot tolerate medication side effects such as weight gain or sexual dysfunction, and people who want a non-drug option. It is not a fit for anyone with metal implants in or near the head (dental fillings are fine) or certain seizure risks. An accelerated protocol called Stanford Neuromodulation Therapy, cleared by the FDA in 2022, compresses treatment into 10 short sessions a day over 5 days, though access is still limited. The NIMH brain stimulation page also covers ECT and vagus nerve stimulation if you want to compare devices.
How Does Spravato Work?
Spravato is a nasal spray form of esketamine, a molecule related to ketamine, that blocks NMDA glutamate receptors. That blockade triggers a short glutamate surge, activates AMPA receptors and sets off rapid synapse growth. Many patients notice changes within days instead of weeks.
The FDA approved Spravato in March 2019 for TRD in combination with an oral antidepressant. In January 2025 it became the first standalone medication approved for adults who had an inadequate response to at least two oral antidepressants. In the trial behind that approval, 22.5% of patients reached remission at week 4 compared with 7.6% on placebo.
What treatment looks like in our Spravato esketamine program:
- Induction: two sessions a week for the first 4 weeks.
- Maintenance: once a week for weeks 5 to 8, then weekly or every other week based on response.
- Monitoring: you self-administer the spray in a certified clinic and stay for at least 2 hours while staff check your blood pressure and side effects.
- Travel: you cannot drive until the next day after a restful sleep, so plan a ride home.
Common side effects include dissociation (feeling detached or "floaty"), dizziness, nausea, sleepiness and a temporary rise in blood pressure. Because of misuse risk, Spravato is only available through a restricted FDA safety program (REMS) and is never sent home with patients. People with uncontrolled high blood pressure, aneurysmal vascular disease or a history of brain bleeding are not candidates.
How Do Psychiatrists Sequence TRD Care?
No single ladder fits everyone, but most specialists follow the same logic: confirm the diagnosis, get the most out of medication, then add device or rapid-acting treatments based on severity, urgency and preference. Most treatment resistant depression options work best layered together rather than tried one at a time. Here is a typical next step after failed antidepressants, mapped by stage:
- Re-check the diagnosis. Screen for bipolar spectrum illness, medical causes, substance use, trauma and sleep disorders. Track change with rating scales such as the PHQ-9 or MADRS instead of impressions.
- Optimize and augment. Raise the dose, switch class, or add an agent with evidence for augmentation. Aripiprazole and brexpiprazole are FDA-approved add-ons for major depression, and lithium and thyroid hormone (T3) have long track records. Your prescriber handles this through medication management.
- Add TMS. TMS is often layered on top of a stable medication regimen, which avoids another round of switching.
- Add or move to Spravato. It is a strong choice when symptoms are severe or speed matters, and it can now be used with or without an oral antidepressant.
- Consider ECT. Electroconvulsive therapy still has the highest remission rates for severe or psychotic depression and remains an option when other steps fail.
Some patients receive TMS and Spravato for TRD in the same care plan, either one after the other or during overlapping weeks. Research on combining them is still early, so the decision should rest on your history, safety factors, and how you respond, reviewed at each visit. Psychotherapy, especially CBT and behavioral activation, keeps running alongside all of these. You can read more about how we pair therapy with medical care on our depression treatment page.
Insurance is a practical factor too. Most commercial plans and Medicare cover TMS and Spravato for documented TRD, but they usually ask for proof of the failed trials, including drug names, doses, and dates. Keeping a simple medication history makes prior authorization much faster.
What Should You Bring to an Evaluation?
Bring a list of every antidepressant you have tried, with the dose, how long you took it, and why you stopped. That one page often saves weeks, because it shows your psychiatrist which treatment resistant depression options make sense right away and which steps you have already covered.
Other details that help:
- Past side effects: weight change, sleep problems, sexual side effects, or emotional numbness.
- Medical history: blood pressure readings, thyroid results, seizure history, and any metal implants.
- Family history: relatives with depression, bipolar disorder, or a strong response to a specific medication.
- Current scores: a recent PHQ-9 if you have one. The PHQ-9 was validated in a 2001 study of 6,000 primary care and OB-GYN patients, and it takes about two minutes.
- Your goals: returning to work, sleeping through the night, or simply getting through the morning without dread.
Be honest about alcohol, cannabis, and missed doses. None of it disqualifies you, and it often explains why a medication seemed not to work. If you are already seeing a therapist, ask them to share notes, since outside observations of your mood over time are useful when staging resistance.
Explore Advanced Depression Care at APA
Advanced Psychiatry Associates offers interventional psychiatry California patients at our clinics, with medication follow-up available by telehealth. Our psychiatrists review your full treatment history, stage your depression, and build a plan that may include TMS, Spravato, augmentation, and therapy. If you are weighing your treatment resistant depression options, the first step is a thorough evaluation. You can schedule an appointment online.
If you are in crisis or having thoughts of suicide, call or text the 988 Suicide & Crisis Lifeline right away.
